Pan-RAF and MEK vertical inhibition enhances therapeutic response in non-V600 BRAF mutant cells

Non-V600BRAF Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal Cancer

(2017) Jeremy C. Jones et al.   JOURNAL OF CLINICAL ONCOLOGY

Combined targeting of Raf and Mek synergistically inhibits tumorigenesis in triple negative breast cancer model systems

(2017) Teddy S. Nagaria et al.   Oncotarget

Histone Deacetylase Inhibitor Treatment Increases the Expression of the Plasma Membrane Ca2+ Pump PMCA4b and Inhibits the Migration of Melanoma Cells Independent of ERK

(2017) Luca Hegedüs et al.   Frontiers in Oncology

A phase Ib study of selumetinib (AZD6244, ARRY-142886) in combination with sorafenib in advanced hepatocellular carcinoma (HCC)

(2016) W. M. Tai et al.   ANNALS OF ONCOLOGY

Clinicopathological features and clinical outcomes associated withTP53andBRAFNon-V600mutations in cutaneous melanoma patients

(2016) Dae Won Kim et al.   CANCER

Clinical characteristics and outcome of patients with lung cancer harboring BRAF mutations

(2016) Claire Tissot et al.   LUNG CANCER

Genomically Driven Tumors and Actionability across Histologies: BRAF-Mutant Cancers as a Paradigm

(2016) M. L. Turski et al.   MOLECULAR CANCER THERAPEUTICS

Effects of RAF inhibitors on PI3K/AKT signalling depend on mutational status of the RAS/RAF signalling axis

(2016) Raphaela Fritsche-Guenther et al.   Oncotarget

Non-p.V600E BRAF Mutations Are Common Using a More Sensitive and Broad Detection Tool

(2015) Jamal Carter et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

A significant response to sorafenib in a woman with advanced lung adenocarcinoma and a BRAF non-V600 mutation

(2015) María Sereno et al.   ANTI-CANCER DRUGS

Clinical detection and categorization of uncommon and concomitant mutations involving BRAF

(2015) Gang Zheng et al.   BMC CANCER

Sorafenib: the gold standard therapy in advanced hepatocellular carcinoma and beyond

(2015) Gennaro Gadaleta-Caldarola et al.   Future Oncology

Targeted Therapy for Patients with BRAF-Mutant Lung Cancer Results from the European EURAF Cohort

(2015) Oliver Gautschi et al.   Journal of Thoracic Oncology

Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma

(2015) Mohammad Atefi et al.   Molecular Cancer

Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Prenylation Inhibition-Induced Cell Death in Melanoma: Reduced Sensitivity in BRAF Mutant/PTEN Wild-Type Melanoma Cells

(2015) Tamás Garay et al.   PLoS One

Trametinib with or without Vemurafenib in BRAF Mutated Non-Small Cell Lung Cancer

(2015) Monika Joshi et al.   PLoS One

Clinical Characteristics and Course of 63 Patients with BRAF Mutant Lung Cancers

(2014) Anya M. Litvak et al.   Journal of Thoracic Oncology

Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma

(2014) Georgina V. Long et al.   NEW ENGLAND JOURNAL OF MEDICINE

Vertical inhibition of the MAPK pathway enhances therapeutic responses inNRAS-mutant melanoma

(2014) Vito W. Rebecca et al.   Pigment Cell & Melanoma Research

RAF Suppression Synergizes with MEK Inhibition in KRAS Mutant Cancer Cells

(2014) Simona Lamba et al.   Cell Reports

RAF Inhibitors Activate the MAPK Pathway by Relieving Inhibitory Autophosphorylation

(2013) Matthew Holderfield et al.   CANCER CELL

Cell migration or cytokinesis and proliferation? – Revisiting the “go or grow” hypothesis in cancer cells in vitro

(2013) Tamás Garay et al.   EXPERIMENTAL CELL RESEARCH

MEK and the inhibitors: from bench to bedside

(2013) Akintunde Akinleye et al.   Journal of Hematology & Oncology

Impact of oncogenic driver mutations on feedback between the PI3K and MEK pathways in cancer cells

(2012) Hiu‑Fung Yuen et al.   BIOSCIENCE REPORTS

Targeting the MAPK–RAS–RAF signaling pathway in cancer therapy

(2012) Libero Santarpia et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Combination of the ERK inhibitor AZD6244 and low-dose sorafenib in a xenograft model of human renal cell carcinoma

(2012) JOHN SHYI PENG YUEN et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

A New Mouse Model for the Study of Human Breast Cancer Metastasis

(2012) Elizabeth Iorns et al.   PLoS One

The crossregulation between ERK and PI3K signaling pathways determines the tumoricidal efficacy of MEK inhibitor

(2012) Jae-Kyung Won et al.   Journal of Molecular Cell Biology

Sorafenib and Mek inhibition is synergistic in medullary thyroid carcinoma in vitro

(2011) Yoon Woo Koh et al.   ENDOCRINE-RELATED CANCER

Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method

(2010) T.-C. Chou   CANCER RESEARCH

Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF

(2010) Sonja J. Heidorn et al.   CELL

Inhibition of MEK/ERK1/2 sensitizes lymphoma cells to sorafenib-induced apoptosis

(2010) Tri K. Nguyen et al.   LEUKEMIA RESEARCH

Drug discovery: Inhibitors that activate

(2010) Karen Cichowski et al.   NATURE

Antitumor Efficacy of the Novel RAF Inhibitor GDC-0879 Is Predicted by BRAFV600E Mutational Status and Sustained Extracellular Signal-Regulated Kinase/Mitogen-Activated Protein Kinase Pathway Suppression

(2009) K. P. Hoeflich et al.   CANCER RESEARCH

In vivo Antitumor Activity of MEK and Phosphatidylinositol 3-Kinase Inhibitors in Basal-Like Breast Cancer Models

(2009) K. P. Hoeflich et al.   CLINICAL CANCER RESEARCH

AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC)

(2009) Hung Huynh et al.   JOURNAL OF HEPATOLOGY

Modeling Genomic Diversity and Tumor Dependency in Malignant Melanoma

(2008) W. M. Lin et al.   CANCER RESEARCH

Elevated CRAF as a Potential Mechanism of Acquired Resistance to BRAF Inhibition in Melanoma

(2008) C. Montagut et al.   CANCER RESEARCH

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling

(2008) Scott M. Wilhelm et al.   MOLECULAR CANCER THERAPEUTICS

CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations

(2008) K S M Smalley et al.   ONCOGENE

Signaling networks assembled by oncogenic EGFR and c-Met

(2008) A. Guo et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA